A-Fib Tied to Adverse Outcomes in Patients Undergoing PCI

Share this content:
A-Fib Tied to Adverse Outcomes in Patients Undergoing PCI
A-Fib Tied to Adverse Outcomes in Patients Undergoing PCI

WEDNESDAY, Aug. 24, 2016 (HealthDay News) -- For patients undergoing percutaneous coronary intervention (PCI), atrial fibrillation (AF) is associated with in-hospital adverse outcomes, according to a study published in the Aug. 30 issue of the Journal of the American College of Cardiology.

Nadia R. Sutton, M.D., M.P.H., from the University of Michigan in Ann Arbor, and colleagues used a prospective multicenter registry to examine the correlation between AF and in-hospital adverse outcomes after PCI. Data were included for 113,283 PCI cases from 47 hospitals.

The researchers found that 12 percent of patients had a history of AF, which varied by institution (2.5 to 18.4 percent). Patients with a history of AF were older at baseline and more likely to have comorbid congestive heart failure, cardiomyopathy, cerebrovascular disease, and chronic lung disease. In-hospital complications, including in-hospital mortality (3 versus 1 percent), were more likely for those with a history of AF. Treatment with a bare-metal stent was more likely for patients with a history of AF in propensity-matched analysis (27 versus 18 percent). Independent associations remained between AF and an increased risk of developing post-procedural bleeding, heart failure, cardiogenic shock, and in-hospital mortality in the propensity-matched model (odds ratios, 1.32, 1.33, 1.26, and 1.41, respectively).

"AF is common among patients undergoing PCI," the authors write. "AF is associated with older age, the presence of other comorbidities, and independently associated with in-hospital post-procedural heart failure, cardiogenic shock, and mortality."

One author disclosed financial ties to Osprey Medical and Blue Cross Blue Shield of Michigan.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »